Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Monday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX stock opened at $1.17 on Monday. Eagle Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $6.81. The stock’s fifty day moving average price is $0.74 and its 200-day moving average price is $1.80.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of large investors have recently made changes to their positions in EGRX. Creative Planning bought a new stake in Eagle Pharmaceuticals during the third quarter valued at approximately $59,000. Jane Street Group LLC bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at $96,000. DGS Capital Management LLC grew its position in shares of Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after acquiring an additional 22,239 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter valued at $453,000. Finally, RBF Capital LLC grew its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares during the period. 85.36% of the stock is currently owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.